SHUBHA RANJAN DUTTA

Dr. SHUBHA RANJAN DUTTA

Department of Pharmacology, Addiction Science, and Toxicology, University of Tennessee Health Science Center, Memphis, Tennessee, USA
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 November 2014 in Irish Journal of Medical Science (1971 -)
Verified
Journal Article
Closed access
PDF file
SHUBHA RANJAN DUTTASHUBHA RANJAN DUTTA
SHUBHA RANJAN DUTTA
DPD. Passi
D. Passi
PSP. Singh
P. Singh
ABA. Bhuibhar
A. Bhuibhar

1 January 2019 in National Journal of Maxillofacial Surgery
Verified
Journal Article
Open access
PDF file
MDManish Dubey
Manish Dubey
DPDeepak Passi
Deepak Passi
GSGeeta Singh
Geeta Singh
SHUBHA RANJAN DUTTASHUBHA RANJAN DUTTA
SHUBHA RANJAN DUTTA
DSDhirendra Srivastava
Dhirendra Srivastava
ASAnchal Srivastava
Anchal Srivastava
Aim/Objective: The mandibular third molar is the most frequently impacted tooth with incidence varies from 9.5% to 68% in different populations. Hence, the aim was to study the prevalence and pattern of mandibular impacted third molar among Delhi-National Capital Region (NCR) population. Materials and Methods: The study was conducted with data collected from registered hospitals and dental clinics of Delhi NCR region. The study represents a retrospective analysis of panoramic radiographs and intraoral periapical radiograph of patients at these centers from June 2014 to June 2016. Results: Out of 960 patients with the third molar investigated, a total of 250 patients having impacted mandibular third molar (152 [60.8%] males and 98 [39.2%]) females between June 2014 and June 2016 were included in the study. The age ranged from 20 to 55 years, with a mean age of 27.6 years and the standard deviation was 5.8 years. The prevalence of impacted mandibular third molars for this study was 26.04%. Conclusion: This study demonstrated that males (60.8%) were more likely to present with impacted mandibular third molars than females (39.2%). The prevalence of third molar impactions was almost the same on both the left (45.8%) and right (54.2%) sides. This study also noted that mesioangular impactions (49.2%) were the most common type of impaction. The least common form of impactions was the transverse types (2%). The prevalence of impacted mandibular third molars for this study was 26.04%.

1 January 2016 in National Journal of Maxillofacial Surgery
Verified
Journal Article
Open access
PDF file
MSMahinder Singh
Mahinder Singh
SHUBHA RANJAN DUTTASHUBHA RANJAN DUTTA
SHUBHA RANJAN DUTTA
DPDeepak Passi
Deepak Passi
PSPurnima Singh
Purnima Singh
SSSarang Sharma
Sarang Sharma
DSDhirendra Srivastava
Dhirendra Srivastava
Aim: The purpose of this study was to compare the efficacy of platelet-rich plasma (PRP), platelet-rich fibrin (PRF), and hydroxyapatite (HA) for reduction of pain and swelling, absence of dry socket, soft tissue healing, and bone regeneration after mandibular third molar extraction in human patients. Materials and Methods: Forty patients requiring extraction of mandibular third molars were randomly grouped as control, PRP, PRF, and HA-treated. The patients were assessed for postoperative pain, swelling, dry socket, and soft tissue healing on the 3rd, 7th, and 14th day of postoperative periods depending on the standard methods. Radiological assessment of the extraction site was done at 1, 2, and 6 months interval to compare the change in bone density in the sockets in control and treated patients. Results: Pain and swelling were less on PRP and PRF site when compared to HA and control site. PRP and PRF site showed better soft tissue healing when compared to HA and control site. Radiographic assessment showed comparatively lesser bone density values in PRP, PRF, and control site at 1, 2, and 6 months than HA site. Conclusion: Our study showed that PRP and PRF are better graft materials than HA regarding pain, swelling, dry socket, and soft tissue healing. Bone regeneration is induced promptly by HA as compared to other graft materials. However, a more elaborate study with a larger number of clinical cases is very much essential to be more conclusive regarding the efficacy of the graft materials.

21 April 2016 in Journal of Maxillofacial and Oral Surgery
Verified
Journal Article
Closed access
PDF file
SHUBHA RANJAN DUTTASHUBHA RANJAN DUTTA
SHUBHA RANJAN DUTTA
PSPurnima Singh
Purnima Singh
DPDeepak Passi
Deepak Passi
DVDon Varghese
Don Varghese
SSSarang Sharma
Sarang Sharma

1 January 2016 in National Journal of Maxillofacial Surgery
Verified
Journal Article
Open access
MSMahinder Singh
Mahinder Singh
SHUBHA RANJAN DUTTASHUBHA RANJAN DUTTA
SHUBHA RANJAN DUTTA
DPDeepak Passi
Deepak Passi
PSPurnima Singh
Purnima Singh
SSSarang Sharma
Sarang Sharma
ASAbhimanyu Sharma
Abhimanyu Sharma
Botulinum neurotoxins, causative agents of botulism in humans, are produced by Clostridium botulinum, an anaerobic spore-former Gram-positive bacillus. Botulinum neurotoxin poses a major bioweapon threat because of its extreme potency and lethality; its ease of production, transport, and misuse; and the need for prolonged intensive care among affected persons. This paper aims at discussing botulinum neurotoxin, its structure, mechanism of action, pharmacology, its serotypes and the reasons for wide use of type A, the various indications and contraindications of the use of botulinum neurotoxin and finally the precautions taken when botulinum neurotoxin is used as a treatment approach. We have searched relevant articles on this subject in various medical databases including Google Scholar, PubMed Central, ScienceDirect, Wiley Online Library, Scopus, and Copernicus. The search resulted in more than 2669 articles, out of which a total of 187 were reviewed. However, the review has been further constricted into only 54 articles as has been presented in this manuscript keeping in mind the page limitation and the limitation to the number of references. A single gram of crystalline toxin, evenly dispersed and inhaled, can kill more than one million people. The basis of the phenomenal potency of botulinum toxin (BT) is enzymatic; the toxin is a zinc proteinase that cleaves neuronal vesicle-associated proteins responsible for acetylcholine release into the neuromuscular junction. A fascinating aspect of BT research in recent years has been the development of the most potent toxin into a molecule of significant therapeutic utility. It is the first biological toxin which is licensed for the treatment of human diseases. The present review focuses on both warfare potential as well as medical uses of botulinum neurotoxin.

23 January 2015 in Journal of Maxillofacial and Oral Surgery
Verified
Journal Article
Closed access
PDF file
SHUBHA RANJAN DUTTASHUBHA RANJAN DUTTA
SHUBHA RANJAN DUTTA
PSPurnima Singh
Purnima Singh
DPDeepak Passi
Deepak Passi
PPPradeep Patter
Pradeep Patter